The Transgenic &Targeting Core Facility is the sole service generating genetically modified mice for the Case CCC and the Cleveland Biomedical community. The services offered are the generation of transgenic and knockout mice, rederivations, in vitro fertilization, generation of chimeric mice, and the design and construction of DNA vectors. The Core began to offer sperm cryopreservation for inbred strains in 2009. The Core provides consultation on scientific, technical and practical matters of mouse genetics. It is the only Transgenic facility in the Cleveland area, and serves investigators at CWRU, University Hospitals, Cleveland Clinic, the VA Hospital, MetroHealth Medical Center, and Kent State University. The facility operates on a fee-for-service basis, and provides consultation with all services. The facility supports the Case CCC mission through the generation of mouse models of cancer, and tools and materials for investigation of basic science questions. The Core is formally accessible by all members of the Case CCC. The Transgenic &Targeting Core Facility is competitive with transgenic cores at other academic institutions in success rates, turnaround, and pricing. As a local service, it has advantages for cancer investigators by direct access to consultation and training, better pricing of services, and control of mouse pathogens. The Core has helped a number of labs with minimal or no experience transition into mouse genetic research programs. In the last funding period the Core has assisted Cancer Center members in: generating mice that model human mutations leading to cancer;identifying cancer susceptibility loci;generating mice for in vivo imaging of tumors;and investigating the basic biology of genes implicated in cancer. Since 2007, Cancer Center members have published 23 peer-reviewed papers with transgenic or knockout mice generated by the facility, and since 2004, transgenic or gene targeted mice created by the Core have been featured in 36 publications by Case CCC members.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8765395
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279
Benson, Bryan L; Li, Lucy; Myers, Jay T et al. (2018) Biomimetic post-capillary venule expansions for leukocyte adhesion studies. Sci Rep 8:9328
Bosca, Federica; Bielecki, Peter A; Exner, Agata A et al. (2018) Porphyrin-Loaded Pluronic Nanobubbles: A New US-Activated Agent for Future Theranostic Applications. Bioconjug Chem 29:234-240

Showing the most recent 10 out of 1227 publications